SCORE! Non-Physician Health Worker (NPHW) Implementation Protocol (SIP)
SIP
1 other identifier
interventional
137
1 country
1
Brief Summary
This study is a substudy of the Strenghtening Community Roots (SCORE!) Cohort study. The investigators will look for people, enrolled in the SCORE! Cohort study, with abnormal results related to blood sugar and fat, as well as high blood pressure and heart disease risks. The investigaors will try to help the community improve sugar, fat and blood pressure through trained people who are not necessarily a medical doctor but have health-sciences-training backgrounds. These people are called Non-Physician Health Workers (NPHW), and they will be under the direction of a medical doctor and will be also in close communication with the participants and the medical doctor to improve their health. This will happen through a total of 12 months, having online and on-site visits, for follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable hypertension
Started Nov 2024
Longer than P75 for not_applicable hypertension
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 11, 2024
CompletedFirst Posted
Study publicly available on registry
November 19, 2024
CompletedStudy Start
First participant enrolled
November 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2029
November 19, 2024
November 1, 2024
4.1 years
October 11, 2024
November 15, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Framinghman risk score (FRS)
A change in Framingham Risk Score from baseline to 12 months. Values are estimated as risk percentages (the likelihood) to have a major adverse cardiovascular events (MACE) within the next 10 years. \< 10 % = Low risk 10-20 % = Intermediate risk \> 20 % = High risk
12 months
Secondary Outcomes (14)
HbA1c
12 months
HbA1c
12 months
Blood pressure
12 months
Blood pressure
12 months
Lipid panel
12 months
- +9 more secondary outcomes
Study Arms (1)
Implementation group.
EXPERIMENTALThe study is based on the HOPE-4 protocol, where trained individuals will support participants in adhering to healthy lifestyle recommendations and support their access to a family physician to follow up on care recommendations. The NPHWs will be allied health professionals (e.g., pharmacists, internationally trained physicians, physiotherapists, nurses). The team will train them on study goals, responsibilities, data management, and follow-up, based on the HOPE-4 training manual. Training will be given once at the beginning of their role and then once annually. The NPHW will support the participant, if needed, in contacting the family doctor and assisting to arrange a follow-up study. If required, the family doctor can contact the NPHW. If further discussion is required or there are questions regarding the study that require further discussion, the NPHW will contact the study physician to address these issues.
Interventions
NPHW will aid participants in accessing a family doctor if required. The family doctor will receive a letter from the study, with suggested medication, based on the HOPE-4 algorithm. The family doctor may decide not to prescribe the recommended treatment or give another treatment (medication). In such case, the participant will still be part of the study and family physician's decision and reason why will be recorded. Follow-up will occur as per the visit schedule. All participants will attend a 20-minute follow-up visits in person at 0, 6 and 12 months, and via telephone at 3 and 9 months. Participants will be assessed to determine if: i. the patient was assessed by their family physician, ii. the family doctor initiated recommended medication treatment(s), iii. they are adhering to the medications as prescribed, iv. they implemented what the NPHW has recommended about dietary and lifestyle changes, using the specific, measurable, achivable, relevant, time-bound (SMART) for goals.
Eligibility Criteria
You may not qualify if:
- Involvement in another study or program that would interfere with the study protocol,
- Known history of coronary artery disease or stroke;
- Severe co-morbid conditions with life expectancy \< 1 year,
- Pregnancy or plans to become pregnant within 12 months;
- Other serious conditions or logistic factors likely to interfere with study participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sonia Anandlead
- McMaster Universitycollaborator
Study Sites (1)
McMaster University
Hamilton, Ontario, L8S 4L8, Canada
Related Publications (1)
Schwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, Camacho PA, Majid F, Bangdiwala SI, Thabane L, Islam S, McKee M, Yusuf S. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Lancet. 2019 Oct 5;394(10205):1231-1242. doi: 10.1016/S0140-6736(19)31949-X. Epub 2019 Sep 2.
PMID: 31488369BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sonia Anand, MD, PhD
McMaster University
- PRINCIPAL INVESTIGATOR
Lita Cameron, MD, MSc
McMaster University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Vice-President, Global Health Department, Professor of Epidemiology, Vascular Medicine Specialist, Principal Investigator
Study Record Dates
First Submitted
October 11, 2024
First Posted
November 19, 2024
Study Start
November 20, 2024
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 1, 2029
Last Updated
November 19, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share
We currently dont have plans for sharing IPD. If this changes in the future, the consent form explains as follow: The participant's personal, identifiable data will not be shared with anyone except with the participant's consent or as required by the laws of the province of Ontario. All information that could identify the participant, such as name and phone number, will only be accessible to the study members who need this information to contact the participant for study purposes (e.g., invite the participant to activities). Before the investigators analyze the data collected, all identifying information will be removed. The de-identified data will be retained until it no longer hold scientific value. If the participant previously consented to sharing of data with other researchers or to data repositories in the main cohort study, data from this study will also be shared. If the participant no longer wish for this to occur the investigators will be notified. HiREB # 17633